| HOME >> BIOLOGY >> TECHNOLOGY |
RALEIGH, N.C., June 17 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that its Clinical Development Practice will conduct two workshops at the 44th Drug Information Association (DIA) Annual Meeting to be held June 22 to 26, 2008, at the Boston Convention and Exhibition Center.
Tim Dietlin, Vice President, will lead a workshop that examines best practices for accelerated study start-up, and Gary Tyson, Senior Vice President, will conduct a workshop that will explore strategies for becoming the sponsor of choice for clinical investigators. In addition to the Campbell Alliance executives leading these sessions, three industry executives will serve on the panel at each of the two workshops.
Mr. Dietlin's workshop, titled "The Keys to Establishing Best Practices for Accelerated Study Start-Up," will be conducted on Monday, June 23 from 3:30 pm to 5:00 pm. The workshop, which is part of the Clinical Research and Development track, will examine best practices and methods for developing a study start-up framework, such as conducting an upfront assessment of an organization's current environment and approaches to study start-up, evaluating the steps that can be taken to streamline operations, and developing training requirements and materials to integrate the framework into daily start-up activities.
"The speed of clinical study start-up can affect an entire clinical trial, and the study team has only one shot at getting it right," Mr. Dietlin said. "Overall success or failure is typically determined well before start-up, so proper planning and management is critical, especially given the ever-increasing complexity of managing the range of activities involved in start-up including technology requirements, site requirements, and general study management."
Mr. Dietlin brings extensive management consulting experience to
Campbell Alliance as a V
'/>"/>
| SOURCE Campbell Alliance Copyright©2008 PR Newswire. All rights reserved |